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the risk of contracting HIV, hepatitis B or C, and the proportion of fatal infections among infected patients (see above) when untreated fresh frozen plasma was used.
For the leukocyte-reduced versus unmodified RBCs in cardiac surgery: mortality at 60 days after operation in recipients of unmodified RBCs and leukocyte-reduced RBCs.
Study designs and other criteria for inclusion in the review
The study designs for the effectiveness evidence results were mainly randomised, controlled trials although no explicit criteria for inclusion were stated.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Five studies were explicitly stated as sources for the estimates of effectiveness.
Methods of combining primary studies
Single studies provided estimates of the parameters of interest.
Investigation of differences between primary studies
Not directly relevant as estimates were based on single studies.
Results of the review
The risk of HIV-1 infection was 1 in 493,000 donor units in random donor platelets. The risk of contracting hepatitis B was 1 in 63,000 donor units, and the risk of contracting hepatitis C was 1 in 103,000 donor units in random donor platelets, and no more than 10% of these infections would be fatal (for hepatitis B, 0.8 in 500,000, and for hepatitis C, 0.5 in 500,000, of such infections were fatal).
Current risk of fatal HIV-1 or hepatitis C and B when untreated fresh-frozen plasma was used were as in the case of the use of random donor platelets. The use of solvent detergent-treated FFP reduced the risk of transmission of hepatitis C and B and HIV-1 to zero.
Mortality at 60 days after operation in recipients of unmodified RBCs was 7.9% compared with 3.6% in recipients of leukocyte-reduced RBCs in one randomised trial. Another study showed a reduction of 2.1% (authors' unpublished data).
Methods used to derive estimates of effectiveness
The authors gave estimates of the numbers of procedures from their own institution and made several assumptions.
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Estimates of effectiveness and key assumptions
The number of units of random donor platelets transfused annually was 27,000.
There were 700 cardiac operations per year and 10,000 units of FFP would be transfused annually.
The main assumptions were as follows:
that a standard random donor platelets is 5 units of platelets and thus, the use of single donor platelets will reduce the risk 5-fold; the case fatality was assumed to be 100% for HIV-1 and 10% each for hepatitis B and C; and the mortality reduction for leukocyte-reduced transfusions in cardiac surgery was assumed to be 2% (smaller than that found in the review).
The potential benefits of leukocyte-reduction in reducing post-operative complications were not considered in the analysis.
Measure of benefits used in the economic analysis
The measure of benefit used was deaths avoided.
Direct costs
The direct incremental costs of the change of technology were estimated. Quantity and cost data were based on the experience in the authors' setting. The quantities given were numbers of procedures as stated earlier. The total annual incremental costs at the authors' institution were reported. The price year was 1999. Some important cost categories may have been omitted from the analysis, such as the cost of avoided fatal complications.
Statistical analysis of costs
No statistical analysis of costs was carried out.
Indirect Costs
No indirect costs were included.
Currency

US dollars ($).
Sensitivity analysis
No sensitivity analyses were performed.
Estimated benefits used in the economic analysis
The number of deaths prevented per year was 0.10 with apheresis platelets, 0.044 with solvent detergent-treated freshfrozen plasma, 14.0 by leukocyte-reduced transfusions, 6.0 by HIV-1 antibody testing, 2.3 by hepatitis B antibody testing, 10 by hepatitis C antibody testing and 0.033 by HIV-1 antigen testing.
Cost results
The annual incremental cost was $1,500,000 for apheresis platelets, $750,000 for solvent detergent-treated fresh-frozen plasma, $160,000 for leukocyte-reduced transfusions (cardiac surgery only), $130,000 for 65,000 components of
